ETF Holdings Breakdown of RGEN

Stock NameRepligen Corporation
TickerRGEN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS7599161095
LEI54930006QJ0T5AUO1E71

News associated with RGEN

Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright
Repligen (NASDAQ:RGEN – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 38.04% from the stock’s previous close. […] - 2025-05-07 05:58:48
Repligen (NASDAQ:RGEN) Given New $190.00 Price Target at JPMorgan Chase & Co.
Repligen (NASDAQ:RGEN – Free Report) had its target price trimmed by JPMorgan Chase & Co. from $200.00 to $190.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock. RGEN has been the subject of several other reports. Wolfe Research raised shares of Repligen […] - 2025-04-30 08:32:52
Repligen (NASDAQ:RGEN) Upgraded by Wolfe Research to Outperform Rating
Wolfe Research upgraded shares of Repligen (NASDAQ:RGEN – Free Report) from a peer perform rating to an outperform rating in a report published on Tuesday, Marketbeat.com reports. They currently have $160.00 price objective on the biotechnology company’s stock. A number of other research firms have also weighed in on RGEN. Royal Bank of Canada upped […] - 2025-04-30 08:32:47
StockNews.com Upgrades Repligen (NASDAQ:RGEN) to “Hold”
Repligen (NASDAQ:RGEN – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. A number of other research analysts have also recently commented on the company. Royal Bank of Canada increased their price target on Repligen from $203.00 to $205.00 and […] - 2025-04-30 07:45:01
Legal & General Group Plc Lowers Stock Position in Repligen Co. (NASDAQ:RGEN)
Legal & General Group Plc trimmed its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 6.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,904 shares of the biotechnology company’s stock after selling 5,698 shares during the quarter. Legal & General […] - 2025-04-17 08:57:10
Federated Hermes Inc. Lowers Holdings in Repligen Co. (NASDAQ:RGEN)
Federated Hermes Inc. reduced its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 98.4% in the 4th quarter, Holdings Channel reports. The fund owned 5,266 shares of the biotechnology company’s stock after selling 316,555 shares during the period. Federated Hermes Inc.’s holdings in Repligen were worth $758,000 as of its most recent […] - 2025-04-16 08:50:56
Repligen Co. (NASDAQ:RGEN) Shares Sold by California Public Employees Retirement System
California Public Employees Retirement System lessened its holdings in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 6.3% in the fourth quarter, HoldingsChannel reports. The fund owned 69,320 shares of the biotechnology company’s stock after selling 4,664 shares during the period. California Public Employees Retirement System’s holdings in Repligen were worth $9,978,000 as of […] - 2025-04-07 08:56:54
Repligen (NASDAQ:RGEN) Stock Rating Upgraded by StockNews.com
StockNews.com upgraded shares of Repligen (NASDAQ:RGEN – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday morning. Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group boosted their target price on shares of Repligen from $165.00 to $170.00 and gave the […] - 2025-04-07 05:31:01
Commonwealth Equity Services LLC Sells 92 Shares of Repligen Co. (NASDAQ:RGEN)
Commonwealth Equity Services LLC cut its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 1.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 6,228 shares of the biotechnology company’s stock after selling 92 shares during the period. Commonwealth Equity Services LLC’s holdings in Repligen were worth $896,000 as of its most recent SEC […] - 2025-04-02 07:34:47
Vanguard Group Inc. Has $734.25 Million Stake in Repligen Co. (NASDAQ:RGEN)
Vanguard Group Inc. boosted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,101,090 shares of the biotechnology company’s stock after buying an additional 56,723 shares during the period. Vanguard Group Inc. owned […] - 2025-03-31 08:10:55
Repligen Co. (NASDAQ:RGEN) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price […] - 2025-03-28 06:08:54
Signaturefd LLC Acquires 124 Shares of Repligen Co. (NASDAQ:RGEN)
Signaturefd LLC lifted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 172.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 196 shares of the biotechnology company’s stock after purchasing an additional 124 shares during the quarter. Signaturefd LLC’s holdings in Repligen were worth $28,000 […] - 2025-03-26 08:27:02
Evercore ISI Begins Coverage on Repligen (NASDAQ:RGEN)
Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN – Get Free Report) in a report released on Tuesday, Marketbeat Ratings reports. The firm set an “in-line” rating and a $155.00 price target on the biotechnology company’s stock. Evercore ISI’s price objective points to a potential upside of 6.99% from the company’s […] - 2025-03-20 06:48:59
21,303 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Proficio Capital Partners LLC
Proficio Capital Partners LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 21,303 shares of the biotechnology company’s stock, valued at approximately $3,066,000. A number of other large investors have also […] - 2025-03-19 07:44:45
M&T Bank Corp Has $427,000 Holdings in Repligen Co. (NASDAQ:RGEN)
M&T Bank Corp cut its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 6.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,969 shares of the biotechnology company’s stock after selling 197 shares during the period. M&T Bank Corp’s […] - 2025-03-14 08:08:51
QRG Capital Management Inc. Has $337,000 Position in Repligen Co. (NASDAQ:RGEN)
QRG Capital Management Inc. reduced its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 35.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,342 shares of the biotechnology company’s stock after selling 1,300 shares during the period. […] - 2025-03-07 09:28:58
Proficio Capital Partners LLC Acquires New Holdings in Repligen Co. (NASDAQ:RGEN)
Proficio Capital Partners LLC bought a new stake in Repligen Co. (NASDAQ:RGEN – Free Report) in the fourth quarter, Holdings Channel reports. The fund bought 21,303 shares of the biotechnology company’s stock, valued at approximately $3,066,000. Other large investors have also recently bought and sold shares of the company. UMB Bank n.a. boosted its holdings […] - 2025-03-06 11:15:38
Contrasting Repligen (NASDAQ:RGEN) & Compass Therapeutics (NASDAQ:CMPX)
Repligen (NASDAQ:RGEN – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership. Valuation and Earnings This table compares Repligen and Compass […] - 2025-03-06 07:39:57
Analysts Set Repligen Co. (NASDAQ:RGEN) Target Price at $181.00
Repligen Co. (NASDAQ:RGEN – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen analysts that are covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokers […] - 2025-03-06 06:45:32
Truist Financial Corp Cuts Stake in Repligen Co. (NASDAQ:RGEN)
Truist Financial Corp reduced its holdings in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 11.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,953 shares of the biotechnology company’s stock after selling 378 shares during the period. Truist Financial Corp’s holdings in Repligen were worth $425,000 as of its most […] - 2025-03-05 11:34:49
New York Life Investment Management LLC Has $801,000 Holdings in Repligen Co. (NASDAQ:RGEN)
New York Life Investment Management LLC cut its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 7.6% in the 4th quarter, HoldingsChannel reports. The fund owned 5,562 shares of the biotechnology company’s stock after selling 455 shares during the quarter. New York Life Investment Management LLC’s holdings in Repligen were worth $801,000 […] - 2025-03-05 10:04:59
Repligen (NASDAQ:RGEN) Downgraded by StockNews.com to Sell
StockNews.com cut shares of Repligen (NASDAQ:RGEN – Free Report) from a hold rating to a sell rating in a research note released on Friday morning. A number of other equities research analysts also recently weighed in on RGEN. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and […] - 2025-02-24 06:40:52
Repligen (NASDAQ:RGEN) Given New $200.00 Price Target at JPMorgan Chase & Co.
Repligen (NASDAQ:RGEN – Get Free Report) had its target price boosted by equities research analysts at JPMorgan Chase & Co. from $190.00 to $200.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […] - 2025-02-23 09:44:58
New York State Teachers Retirement System Sells 100 Shares of Repligen Co. (NASDAQ:RGEN)
New York State Teachers Retirement System lowered its stake in Repligen Co. (NASDAQ:RGEN – Free Report) by 0.2% during the fourth quarter, Holdings Channel reports. The firm owned 53,932 shares of the biotechnology company’s stock after selling 100 shares during the period. New York State Teachers Retirement System’s holdings in Repligen were worth $7,763,000 at […] - 2025-02-19 09:17:18
Repligen (NASDAQ:RGEN) Coverage Initiated at TD Cowen
Equities research analysts at TD Cowen initiated coverage on shares of Repligen (NASDAQ:RGEN – Get Free Report) in a note issued to investors on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $200.00 price target on the biotechnology company’s stock. TD Cowen’s price target points to a potential upside of 33.79% […] - 2025-02-12 06:59:03
Yousif Capital Management LLC Sells 867 Shares of Repligen Co. (NASDAQ:RGEN)
Yousif Capital Management LLC lessened its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 5.1% during the 4th quarter, HoldingsChannel reports. The firm owned 16,237 shares of the biotechnology company’s stock after selling 867 shares during the quarter. Yousif Capital Management LLC’s holdings in Repligen were worth $2,337,000 as of its most […] - 2025-02-11 08:40:56

RGEN institutional holdings

The following institutional investment holdings of RGEN have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 33,931USD 4,338,078
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 30,265USD 3,869,380
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 67,702USD 8,655,701
2025-05-08 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 90USD 11,507 0.8%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 785USD 100,362
2025-05-08 IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF) 334USD 42,702
Total =133,107 USD 17,017,730
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.